Form: 8-K

Current report filing

February 5, 2018

Documents

Exhibit 99.1

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—UNITED STATES

(Unaudited; Amounts in millions)

 

    A    B     C      D     E      F     G     H    

I=A+B+C+D  

+E+F+G+H  
   

BDX as  

Reported  

    BD
Realign
BUs		     Bard as
Reported		      Bard Realign
BUs		     Bard Align
Region
Reporting		      Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		    

Total  

NewCo as  

Adjusted  
         FN#1     FN#2      FN#3     FN#4      FN#5     FN#6     FN#7      

12 Months Ended September 30, 2016

                     

BD MEDICAL

                     

Medication Delivery Solutions (previously Medication and Procedural Solutions)

     1,959        (599 )      —          556       1        (19 )      —         (14 )      1,883  

Medication Management Solutions

     1,779        —         —          —         —          —         —         —         1,779  

Diabetes Care

     521        —         —          —         —          —         —         —         521  

Pharmaceutical Systems

     328        —         —          —         —          —         —         —         328  

Respiratory Solutions

     559        —         —          —         —          (559 )      —         —         —    
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     5,144        (599 )      —          556       1        (578 )      —         (14 )      4,510  
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

BD LIFE SCIENCES

                     

Preanalytical Systems

     715        —         —          —         —          —         —         —         715  

Diagnostic Systems

     600        —         —          —         —          —         —         —         600  

Biosciences

     433        —         —          —         —          —         —         —         433  
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     1,748        —         —          —         —          —         —         —         1,748  
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

BD INTERVENTIONAL

                     

Surgery

     —          585       —          498       2        (37 )      —         —         1,047  

Peripheral Intervention

     —          14       —          822       3        —         (158 )      —         682  

Urology and Critical Care

     —          —         —          635       1        —         —         —         635  

Legacy Bard Product Groups

                     

Vascular

     —          —         637        (637 )      —          —         —         —         —    

Urology

     —          —         636        (636 )      —          —         —         —         —    

Oncology

     —          —         691        (691 )      —          —         —         —         —    

Surgical Specialties

     —          —         480        (480 )      —          —         —         —         —    

Other

     —          —         67        (67 )      —          —         —         —         —    
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     —          599       2,511        (556 )      5        (37 )      (158 )      —         2,364  
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL UNITED STATES

     6,893        —         2,511        —         6        (615 )      (158 )      (14 )      8,622  
 

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 1

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—UNITED STATES

(Unaudited; Amounts in millions)

 

    A     B     C     D     E     F     G     H     I=A+B+C+D
+E+F+G+H		       J     K=(I-J)/J  
   

BDX as  

Reported  

   BD
Realign
BUs		     Bard as
Reported		     Bard Realign
BUs		     Bard Align
Region
Reporting		     Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		    

Total NewCo  

as Adjusted  

      

PY  

Comparable  

Period  

   Reported %
Change		  
        FN#1     FN#2     FN#3     FN#4     FN#5     FN#6     FN#7                    

12 Months Ended September 30, 2017

                        

BD MEDICAL

                        

Medication Delivery Solutions (previously Medication and Procedural Solutions)

     1,968       (591 )      —         571       1       —         —         (14 )      1,935         1,883       2.8%  

Medication Management Solutions

     1,843       —         —         —         —         —         —         —         1,843         1,779       3.6%  

Diabetes Care

     546       —         —         —         —         —         —         —         546         521       4.9%  

Pharmaceutical Systems

     328       —         —         —         —         —         —         —         328         328       0.1%  

Respiratory Solutions

     —         —         —         —         —         —         —         —         —           —         NM  
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

TOTAL

     4,685       (591 )      —         571       1       —         —         (14 )      4,652         4,510       3.2%  
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

BD LIFE SCIENCES

                        

Preanalytical Systems

     741       —         —         —         —         —         —         —         741         715       3.7%  

Diagnostic Systems

     622       —         —         —         —         —         —         —         622         600       3.7%  

Biosciences

     455       —         —         —         —         —         —         —         455         433       4.9%  
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

TOTAL

     1,818       —         —         —         —         —         —         —         1,818         1,748       4.0%  
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

BD INTERVENTIONAL

                        

Surgery

     —         577       —         511       2       (39 )      —         —         1,051         1,047       0.4%  

Peripheral Intervention

     —         14       —         875       3       —         (173 )      —         718         682       5.4%  

Urology and Critical Care

     —         —         —         681       —         —         —         —         681         635       7.2%  

Legacy Bard Product Groups

                        

Vascular

     —         —         687       (687 )      —         —         —         —         —           —      

Urology

     —         —         676       (676 )      —         —         —         —         —           —      

Oncology

     —         —         714       (714 )      —         —         —         —         —           —      

Surgical Specialties

     —         —         491       (491 )      —         —         —         —         —           —      

Other

     —         —         71       (71 )      —         —         —         —         —           —      
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

TOTAL

     —         591       2,638       (571 )      5       (39 )      (173 )      —         2,451         2,364       3.7%  
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

TOTAL UNITED STATES

     6,504       —         2,638       —         6       (39 )      (173 )      (14 )      8,921         8,622       3.5%  
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

  

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 2

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL

(Unaudited; Amounts in millions)

 

     A      B     C      D     E     F     G      H     

I=A+B+C+D  

+E+F+G+H  
    

BDX as  

Reported  

    BD
Realign
BUs		     Bard as
Reported		      Bard Realign
BUs		     Bard Align
Region
Reporting		     Divestiture
Adjust		     Gore Royalty
Classification
Adjust		      Interco
Adjust		     

Total NewCo  

as Adjusted  
          FN#1     FN#2      FN#3     FN#4     FN#5     FN#6      FN#7       

12 Months Ended September 30, 2016

                       

BD MEDICAL

                       

Medication Delivery Solutions (previously Medication and Procedural Solutions)

      1,454        (92 )      —          198       (1 )      —         —          —          1,559  

Medication Management Solutions

      419        —         —          —         —         —         —          —          419  

Diabetes Care

      502        —         —          —         —         —         —          —          502  

Pharmaceutical Systems

      872        —         —          —         —         —         —          —          872  

Respiratory Solutions

      263        —         —          —         —         (263 )      —          —          —    
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

TOTAL

      3,510        (92 )      —          198       (1 )      (263 )      —          —          3,351  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

BD LIFE SCIENCES

                       

Preanalytical Systems

      694        —         —          —         —         —         —          —          694  

Diagnostic Systems

      701        —         —          —         —         —         —          —          701  

Biosciences

      685        —         —          —         —         —         —          —          685  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

TOTAL

      2,080        —         —          —         —         —         —          —          2,080  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

BD INTERVENTIONAL

                       

Surgery

      —          87       —          143       (2 )      (10 )      —          —          218  

Peripheral Intervention

      —          5       —          466       (3 )      —         —          —          468  

Urology and Critical Care

      —          —         —          300       (1 )      —         —          —          299  

Legacy Bard Product Groups

                       

Vascular

      —          —         355        (355 )      —         —         —          —          —    

Urology

      —          —         281        (281 )      —         —         —          —          —    

Oncology

      —          —         299        (299 )      —         —         —          —          —    

Surgical Specialties

      —          —         143        (143 )      —         —         —          —          —    

Other

      —          —         29        (29 )      —         —         —          —          —    
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

TOTAL

      —          92       1,107        (198 )      (5 )      (10 )      —          —          986  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

TOTAL INTERNATIONAL

      5,590        —         1,107        —         (6 )      (274 )      —          —          6,418  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

     

 

 

     

 

 

 

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 3

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—INTERNATIONAL

(Unaudited; Amounts in millions)

 

    A     B     C     D     E     F     G     H    

I=A+B+C+D  

+E+F+G+H  

         J     K=(I-J)/J     L=(I-J-M)/J     M  
   

BDX as  

Reported  

   BD
Realign
BUs		     Bard as
Reported		     Bard
Realign
BUs		     Bard Align
Region
Reporting		     Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		    

Total  

NewCo as  

Adjusted  

        

PY  

Comparable  

Period  

   Reported %
Change		     FXN %
Change		     FX
Impact		  
        FN#1     FN#2     FN#3     FN#4     FN#5     FN#6     FN#7                                  

12 Months Ended September 30, 2017

                            

BD MEDICAL

                            

Medication Delivery Solutions (previously Medication and Procedural Solutions)

     1,529       (95 )      —         229       (1 )      —         —         —         1,663         1,559       6.7%       8.1%       (23 ) 

Medication Management Solutions

     452       —         —         —         —         —         —         —         452         419       7.9%       10.6%       (11 ) 

Diabetes Care

     510       —         —         —         —         —         —         —         510         502       1.6%       2.2%       (3 ) 

Pharmaceutical Systems

     929       —         —         —         —         —         —         —         929         872       6.6%       7.3%       (6 ) 

Respiratory Solutions

     —         —         —         —         —         —         —         —         —           —         NM       NM       —    
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL

     3,419       (95 )      —         229       (1 )      —         —         —         3,553         3,351       6.0%       7.3%       (44 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

BD LIFE SCIENCES

                            

Preanalytical Systems

     730       —         —         —         —         —         —         —         730         694       5.2%       6.8%       (11 ) 

Diagnostic Systems

     756       —         —         —         —         —         —         —         756         701       7.9%       8.8%       (6 ) 

Biosciences

     684       —         —         —         —         —         —         —         684         685       -0.2%       0.8%       (7 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL

     2,170       —         —         —         —         —         —         —         2,170         2,080       4.3%       5.5%       (24 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

BD INTERVENTIONAL

                            

Surgery

     —         89       —         169       (2 )      (10 )      —         —         247         218       12.9%       16.5%       (8 ) 

Peripheral Intervention

     —         6       —         518       (3 )      —         —         —         521         468       11.1%       12.6%       (7 ) 

Urology and Critical Care

     —         —         —         321       —         —         —         —         320         299       7.0%       10.3%       (10 ) 

Legacy Bard Product Groups

                            

Vascular

     —         —         398       (398 )      —         —         —         —         —           —          

Urology

     —         —         305       (305 )      —         —         —         —         —           —          

Oncology

     —         —         338       (338 )      —         —         —         —         —           —          

Surgical Specialties

     —         —         169       (169 )      —         —         —         —         —           —          

Other

     —         —         27       (27 )      —         —         —         —         —           —          
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL

     —         95       1,237       (229 )      (5 )      (10 )      —         —         1,088         986       10.3%       12.8%       (24 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL INTERNATIONAL

     5,589       —         1,237       —         (6 )      (10 )      —         —         6,811         6,418       6.1%       7.6%       (92 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 4

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—TOTAL

(Unaudited; Amounts in millions)

 

     A      B     C      D     E      F     G     H    

I=A+B+C+D  

+E+F+G+H  
    

BDX as  

Reported  

    BD
Realign
BUs		     Bard as
Reported		      Bard Realign
BUs		     Bard Align
Region
Reporting		      Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		    

Total NewCo  

as Adjusted  
          FN#1     FN#2      FN#3     FN#4      FN#5     FN#6     FN#7      

12 Months Ended September 30, 2016

                      

BD MEDICAL

                      

Medication Delivery Solutions (previously Medication and Procedural Solutions)

      3,413        (692 )      —          754       —          (19 )      —         (14 )      3,442  

Medication Management Solutions

      2,197        —         —          —         —          —         —         —         2,197  

Diabetes Care

      1,023        —         —          —         —          —         —         —         1,023  

Pharmaceutical Systems

      1,199        —         —          —         —          —         —         —         1,199  

Respiratory Solutions

      822        —         —          —         —          (822 )      —         —         —    
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

      8,654        (692 )      —          754       —          (842 )      —         (14 )      7,861  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

BD LIFE SCIENCES

                      

Preanalytical Systems

      1,409        —         —          —         —          —         —         —         1,409  

Diagnostic Systems

      1,301        —         —          —         —          —         —         —         1,301  

Biosciences

      1,119        —         —          —         —          —         —         —         1,119  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

      3,829        —         —          —         —          —         —         —         3,829  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

BD INTERVENTIONAL

                      

Surgery

      —          672       —          641       —          (47 )      —         —         1,266  

Peripheral Intervention

      —          20       —          1,288       —          —         (158 )      —         1,150  

Urology and Critical Care

      —          —         —          935       —          —         —         —         935  

Legacy Bard Product Groups

                      

Vascular

      —          —         992        (992 )      —          —         —         —         —    

Urology

      —          —         917        (917 )      —          —         —         —         —    

Oncology

      —          —         991        (991 )      —          —         —         —         —    

Surgical Specialties

      —          —         623        (623 )      —          —         —         —         —    

Other

      —          —         95        (95 )      —          —         —         —         —    
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

      —          692       3,618        (754 )      —          (47 )      (158 )      —         3,350  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL WORLDWIDE

      12,483        —         3,618        —         —          (889 )      (158 )      (14 )      15,040  
  

 

 

 

   

 

 

    

 

 

     

 

 

    

 

 

     

 

 

    

 

 

    

 

 

    

 

 

 

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL

(Unaudited; Amounts in millions)

 

    A   B     C     D     E     F     G     H    

I=A+B+C+D  

+E+F+G+H  

       J     K=(I-J)/J     L=(I-J-M)/J     M  
    BDX as
Reported		   BD
Realign
BUs		     Bard as
Reported		     Bard Realign
BUs		     Bard Align
Region
Reporting		     Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		    

Total NewCo  

as Adjusted  

      

PY  

Comparable  

Period  

   Reported
%
Change		     FXN %
Change		     FX
Impact		  
        FN#1     FN#2     FN#3     FN#4     FN#5     FN#6     FN#7                                

12 Months Ended September 30, 2017

                            

BD MEDICAL

                            

Medication Delivery Solutions (previously Medication and Procedural Solutions)

     3,497       (685 )      —         800       —         —         —         (14 )      3,598         3,442       4.5%       5.2%       (23 ) 

Medication Management Solutions

     2,295       —         —         —         —         —         —         —         2,295         2,197       4.4%       4.9%       (11 ) 

Diabetes Care

     1,056       —         —         —         —         —         —         —         1,056         1,023       3.3%       3.6%       (3 ) 

Pharmaceutical Systems

     1,256       —         —         —         —         —         —         —         1,256         1,199       4.8%       5.3%       (6 ) 

Respiratory Solutions

     —         —         —         —         —         —         —         —         —           —         NM       NM       —    
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL

     8,105       (685 )      —         800       —         —         —         (14 )      8,205         7,861       4.4%       4.9%       (44 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

BD LIFE SCIENCES

                            

Preanalytical Systems

     1,471       —         —         —         —         —         —         —         1,471         1,409       4.4%       5.2%       (11 ) 

Diagnostic Systems

     1,378       —         —         —         —         —         —         —         1,378         1,301       5.9%       6.4%       (6 ) 

Biosciences

     1,139       —         —         —         —         —         —         —         1,139         1,119       1.8%       2.4%       (7 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL

     3,988       —         —         —         —         —         —         —         3,988         3,829       4.2%       4.8%       (24 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

BD INTERVENTIONAL

                            

Surgery

     —         666       —         680       —         (48 )      —         —         1,298         1,266       2.6%       3.2%       (8 ) 

Peripheral Intervention

     —         19       —         1,393       —         —         (173 )      —         1,239         1,150       7.7%       8.3%       (7 ) 

Urology and Critical Care

     —         —         —         1,002       —         —         —         —         1,002         935       7.2%       8.2%       (10 ) 

Legacy Bard Product Groups

                            

Vascular

     —         —         1,085       (1,085 )      —         —         —         —         —           —          

Urology

     —         —         980       (980 )      —         —         —         —         —           —          

Oncology

     —         —         1,052       (1,052 )      —         —         —         —         —           —          

Surgical Specialties

     —         —         660       (660 )      —         —         —         —         —           —          

Other

     —         —         98       (98 )      —         —         —         —         —           —          
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL

     —         685       3,875       (800 )      —         (48 )      (173 )      —         3,539         3,350       5.6%       6.4%       (24 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

TOTAL WORLDWIDE

     12,093       —         3,875       —         —         (48 )      (173 )      (14 )      15,732         15,040       4.6%       5.2%       (92 ) 
 

 

 

 

  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

    

 

 

 

  

 

 

    

 

 

    

 

 

  

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—EMERGING & DEVELOPED MARKETS, CHINA

(Unaudited; Amounts in millions)

 

     A      B      C      D      E     F     G     H    

I=A+B+C+D

+E+F+G+H

  
     BDX as
Reported		      BD
Realign
BUs		      Bard as
Reported		      Bard
Realign
BUs		      Bard
Align
Region
Reporting		     Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		     Total
NewCo as
Adjusted		  
            FN#1      FN#2      FN#3      FN#4     FN#5     FN#6     FN#7        

12 Months Ended September 30, 2016

                       

EMERGING MARKETS

      1,904        —          363        —          (29 )      (107 )      —         —         2,132  

DEVELOPED MARKETS

      10,579        —          3,254        —          29       (782 )      (158 )      (14 )      12,908  

CHINA

      663        —          215        —          —         (23 )      —         —         855  

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 7

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—EMERGING & DEVELOPED MARKETS, CHINA

(Unaudited; Amounts in millions)

 

    A       B     C     D     E     F     G     H    

I=A+B+C+D  

+E+F+G+H  

         J       K=(I-J)/J     L=(I-J-M)/J     M  
   

BDX as  

Reported  

     BD
Realign
BUs		     Bard as
Reported		     Bard
Realign
BUs		     Bard Align
Region
Reporting		     Divestiture
Adjust		     Gore Royalty
Classification
Adjust		     Interco
Adjust		    

Total NewCo  

as Adjusted  

        

PY  

Comparable  

Period  

     Reported %
Change		     FXN %
Change		     FX
Impact		  
          FN#1     FN#2     FN#3     FN#4     FN#5     FN#6     FN#7                                    

12 Months Ended September 30, 2017

                            

EMERGING MARKETS

     1,953       —         434       —         (33 )      (2 )      —         —         2,352         2,132       10.3 %      12.0 %      (36 ) 

DEVELOPED MARKETS

     10,140       —         3,442       —         33       (46 )      (173 )      (14 )      13,380         12,908       3.7 %      4.1 %      (56 ) 

CHINA

     686       —         254       —         —         (1 )      —         —         940         855       9.9 %      14.5 %      (39 ) 

Footnote Explanations

 

1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.
3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.
4 Represents re-alignment of Bard country reporting to align to BD’s existing presentation.
5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

 

Page 8